使用尼马曲韦/利托那韦治疗癫痫患者：国际抗癫痫联盟以色列分会的最新进展。
Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy.
机构信息
Pediatric Neurology Unit, Soroka University Medical Center, Beer Sheva, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
出版信息
Epilepsia. 2022 May;63(5):1276-1278. doi: 10.1111/epi.17212. Epub 2022 Mar 9.
Abstract
Presented herein are recommendations for use of nirmatrelvir/ritonavir in patients with epilepsy, as issued by the Steering Committee of the Israeli chapter of the International League Against Epilepsy. The recommendations suggest that patients on moderate-to-strong enzyme-inducing antiseizure medications (ASMs) and everolimus should not be treated with nirmatrelvir/ritonavir; rectal diazepam may be used as an alternative to buccal midazolam; doses of ASMs that are cytochrome P450 (CYP3A4) substrates might be adjusted; and patients treated with combinations of nirmatrelvir/ritonavir and ASMs that are CYP3A4 substrates or lamotrigine should be monitored for drug efficacy and adverse drug reactions.
摘要
本文介绍了国际抗癫痫联盟以色列分会指导委员会发布的尼马曲韦/利托那韦在癫痫患者中的使用建议。建议指出，正在使用中-强酶诱导性抗癫痫药物（ASMs）和依维莫司的患者不应使用尼马曲韦/利托那韦；直肠地西泮可用作口腔咪达唑仑的替代药物；细胞色素 P450（CYP3A4）底物的 ASMs 剂量可能需要调整；接受尼马曲韦/利托那韦联合使用的患者 CYP3A4 底物或拉莫三嗪应监测药物疗效和不良反应。
相似文献
1
Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy.使用尼马曲韦/利托那韦治疗癫痫患者：国际抗癫痫联盟以色列分会的最新进展。
Epilepsia. 2022 May;63(5):1276-1278. doi: 10.1111/epi.17212. Epub 2022 Mar 9.
2
Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy.尼马瑞韦（nirmatrelvir）与利托那韦（ritonavir）增效制剂的临床相关药物相互作用及对癫痫患者 COVID-19 管理的影响。
Clin Pharmacokinet. 2022 Sep;61(9):1219-1236. doi: 10.1007/s40262-022-01152-z. Epub 2022 Jul 27.
3
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.新型冠状病毒肺炎患者接受奈玛特韦/利托那韦联合免疫抑制剂治疗时的治疗药物监测和剂量调整。
Ther Drug Monit. 2023 Apr 1;45(2):191-199. doi: 10.1097/FTD.0000000000001014.
4
COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed.COVID-19 与抗癫痫药物：尼马曲韦/利托那韦合并用药时的实践指导方法。
Eur J Clin Pharmacol. 2022 Oct;78(10):1697-1701. doi: 10.1007/s00228-022-03370-7. Epub 2022 Aug 5.
5
Generic substitutions of antiseizure medications: recommendations issued by the Israeli Chapter of the International League Against Epilepsy.抗癫痫药物的通用替代：国际抗癫痫联盟以色列分会发布的建议
Epileptic Disord. 2022 Oct 1;24(5):973-975. doi: 10.1684/epd.2022.1469.
6
Treating Epilepsy Patients with Investigational Anti-COVID-19 Drugs: Recommendations by the Israeli Chapter of the ILAE.使用抗新冠病毒研究性药物治疗癫痫患者：国际抗癫痫联盟以色列分会的建议
Isr Med Assoc J. 2020 Nov;11(22):665-672.
7
Oral Drugs Against COVID-19.口服抗新冠病毒药物。
Dtsch Arztebl Int. 2022 Apr 15;119(15):263-269. doi: 10.3238/arztebl.m2022.0152.
8
Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.尼马瑞韦/利托那韦联合他克莫司用于肺移植受者：一项单中心病例系列研究。
Transplantation. 2023 May 1;107(5):1200-1205. doi: 10.1097/TP.0000000000004394. Epub 2022 Oct 28.
9
Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.COVID-19 感染患儿在使用奈玛特韦/利托那韦（Paxlovid）治疗后，他的他克莫司水平升高。
Pediatr Nephrol. 2023 Apr;38(4):1387-1388. doi: 10.1007/s00467-022-05712-0. Epub 2022 Aug 19.
10
Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications.癫痫患者在抗癫痫药物短缺时的治疗策略建议。
Epileptic Disord. 2022 Oct 1;24(5):751-764. doi: 10.1684/epd.2022.1468.
引用本文的文献
1
COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed.COVID-19 与抗癫痫药物：尼马曲韦/利托那韦合并用药时的实践指导方法。
Eur J Clin Pharmacol. 2022 Oct;78(10):1697-1701. doi: 10.1007/s00228-022-03370-7. Epub 2022 Aug 5.
2
Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy.尼马瑞韦（nirmatrelvir）与利托那韦（ritonavir）增效制剂的临床相关药物相互作用及对癫痫患者 COVID-19 管理的影响。
Clin Pharmacokinet. 2022 Sep;61(9):1219-1236. doi: 10.1007/s40262-022-01152-z. Epub 2022 Jul 27.
本文引用的文献
1
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
2
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.口服生物可利用的SARS-CoV-2 3C样蛋白酶抑制剂奈玛特韦在动物和人类中的处置情况。
Drug Metab Dispos. 2022 May;50(5):576-590. doi: 10.1124/dmd.121.000801. Epub 2022 Feb 13.
3
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.在新冠肺炎患者中停用洛匹那韦/利托那韦：药物相互作用效应的持续时间。
J Antimicrob Chemother. 2020 Oct 1;75(10):3084-3086. doi: 10.1093/jac/dkaa253.
4
Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.酶抑制作用对吡仑帕奈药代动力学的影响：研究设计为何重要。
Epilepsy Res. 2017 Aug;134:41-48. doi: 10.1016/j.eplepsyres.2017.04.018. Epub 2017 Apr 26.
5
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.在药物相互作用研究中，利托那韦作为细胞色素P450 - 3A的指标性抑制剂，是酮康唑的最佳替代药物。
Br J Clin Pharmacol. 2015 Sep;80(3):342-50. doi: 10.1111/bcp.12668. Epub 2015 Jun 1.
6
Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.循证指南：艾滋病毒/艾滋病患者的抗癫痫药物选择：美国神经病学学会质量标准分会和国际抗癫痫联盟治疗策略特别委员会特设工作组的报告。
Neurology. 2012 Jan 10;78(2):139-45. doi: 10.1212/WNL.0b013e31823efcf8. Epub 2012 Jan 4.
7
Characterization of the time course of carbamazepine deinduction by an enzyme turnover model.用酶转化模型对卡马西平诱导缺失的时程特征进行描述。
Clin Pharmacokinet. 2009;48(5):313-20. doi: 10.2165/00003088-200948050-00003.
8
Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.利托那韦对肝脏CYP3A活性及埃替格韦口服暴露量的剂量反应。
Clin Pharmacol Ther. 2009 Jan;85(1):64-70. doi: 10.1038/clpt.2008.168. Epub 2008 Sep 24.
Zotero 插件